Tyro3 receptor tyrosine kinase contributes to pathogenic phenotypes of fibroblast-like synoviocytes in rheumatoid arthritis and disturbs immune cell balance in experimental arthritis

Copyright © 2023 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 255(2023) vom: 15. Okt., Seite 109753
1. Verfasser: Wang, Ziye (VerfasserIn)
Weitere Verfasser: Zhao, Zhen, Li, Zhichang, Xu, Liling, Li, Hongchao, Zhu, Huaqun, Cheng, Gong, Yao, RanRan, Pei, Wenwen, Liang, Ruyu, Liang, Renge, Ye, Hua, Jiang, Shan, Niu, Haitao, Sun, Xiaolin, Su, Yin
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Fibroblast like synoviocyte K/BxN serum transfer arthritis Rheumatoid arthritis Tyro3TK Protein-Tyrosine Kinases EC 2.7.10.1 Receptor Protein-Tyrosine Kinases Tyro3 protein, mouse TYRO3 protein, human
LEADER 01000caa a22002652c 4500
001 NLM361763220
003 DE-627
005 20250305054920.0
007 cr uuu---uuuuu
008 231226s2023 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2023.109753  |2 doi 
028 5 2 |a pubmed25n1205.xml 
035 |a (DE-627)NLM361763220 
035 |a (NLM)37678714 
035 |a (PII)S1521-6616(23)00516-8 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Wang, Ziye  |e verfasserin  |4 aut 
245 1 0 |a Tyro3 receptor tyrosine kinase contributes to pathogenic phenotypes of fibroblast-like synoviocytes in rheumatoid arthritis and disturbs immune cell balance in experimental arthritis 
264 1 |c 2023 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 02.10.2023 
500 |a Date Revised 02.05.2024 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2023 Elsevier Inc. All rights reserved. 
520 |a Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterized by synovitis and joint damage, the underlying causes of which remain unclear. Our prior investigations revealed a notable correlation between the expression of Tyro3 Protein Tyrosine Kinase (Tyro3TK) and the progression of RA. To further elucidate the pathogenic role of Tyro3TK in RA, we analyzed the influence of Tyro3TK on pathogenic phenotypes of RA fibroblast like synoviocyte (FLS) in vitro and compared disease severity, joint damages and immunological parameters of K/BxN serum transfer arthritis (STA) in Tyro3TK-/- deficient mice and wild type controls. Our findings underscored the remarkable effectiveness of Tyro3TK blockade, as evidenced by diminished secretion of inflammatory cytokines and matrix metalloproteinases (MMPs), curtailed migration and invasiveness of RAFLS, and attenuated differentiation of pathogenic helper T cell subsets mediated by RAFLS. Correspondingly, our in vivo investigations illuminated the more favorable outcomes in Tyro3TK-deficient mice, characterized by reduced joint pathology, tempered synovial inflammation, and restored immune cell equilibrium. These data suggested that Tyro3TK might contribute to aggravated autoimmune arthritis and immunological pathology and act as a potential therapeutic target for RA 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Fibroblast like synoviocyte 
650 4 |a K/BxN serum transfer arthritis 
650 4 |a Rheumatoid arthritis 
650 4 |a Tyro3TK 
650 7 |a Protein-Tyrosine Kinases  |2 NLM 
650 7 |a EC 2.7.10.1  |2 NLM 
650 7 |a Receptor Protein-Tyrosine Kinases  |2 NLM 
650 7 |a EC 2.7.10.1  |2 NLM 
650 7 |a Tyro3 protein, mouse  |2 NLM 
650 7 |a EC 2.7.10.1  |2 NLM 
650 7 |a TYRO3 protein, human  |2 NLM 
650 7 |a EC 2.7.10.1  |2 NLM 
700 1 |a Zhao, Zhen  |e verfasserin  |4 aut 
700 1 |a Li, Zhichang  |e verfasserin  |4 aut 
700 1 |a Xu, Liling  |e verfasserin  |4 aut 
700 1 |a Li, Hongchao  |e verfasserin  |4 aut 
700 1 |a Zhu, Huaqun  |e verfasserin  |4 aut 
700 1 |a Cheng, Gong  |e verfasserin  |4 aut 
700 1 |a Yao, RanRan  |e verfasserin  |4 aut 
700 1 |a Pei, Wenwen  |e verfasserin  |4 aut 
700 1 |a Liang, Ruyu  |e verfasserin  |4 aut 
700 1 |a Liang, Renge  |e verfasserin  |4 aut 
700 1 |a Ye, Hua  |e verfasserin  |4 aut 
700 1 |a Jiang, Shan  |e verfasserin  |4 aut 
700 1 |a Niu, Haitao  |e verfasserin  |4 aut 
700 1 |a Sun, Xiaolin  |e verfasserin  |4 aut 
700 1 |a Su, Yin  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 255(2023) vom: 15. Okt., Seite 109753  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnas 
773 1 8 |g volume:255  |g year:2023  |g day:15  |g month:10  |g pages:109753 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2023.109753  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 255  |j 2023  |b 15  |c 10  |h 109753